Discovery of Novel Cysteine Protease Inhibitors for the Treatment of Coronavirus (COVID-19)


Дәйексөз келтіру

Толық мәтін

Аннотация

The application describes compounds, such as compounds of general Formula, with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and synthetic methods of various compounds with warheads are included. The compounds are inhibitors of proteases, such as the 3C, CL- or 3CL-like protease.

Авторлар туралы

Surya De

Department of Chemistry, Conju-Probe, San Diego

Хат алмасуға жауапты Автор.
Email: info@benthamscience.net

Әдебиет тізімі

  1. Ábrányi-Balogh, P.; Petri, L.; Imre, T.; Szijj, P.; Scarpino, A.; Hrast, M. Mitrović A.; Fonovič U.P.; Németh, K.; Barreteau, H.; Roper, D.I.; Horváti, K.; Ferenczy, G.G.; Kos, J.; Ilaš, J.; Gobec, S.; Keserű G.M. A road map for prioritizing warheads for cysteine targeting covalent inhibitors. Eur. J. Med. Chem., 2018, 160, 94-107. doi: 10.1016/j.ejmech.2018.10.010 PMID: 30321804
  2. Yu, W.; Zhao, Y.; Ye, H.; Wu, N.; Liao, Y.; Chen, N.; Li, Z.; Wan, N.; Hao, H.; Yan, H.; Xiao, Y.; Lai, M. Structure-based design of a dual-targeted covalent inhibitor against papain-like and main proteases of SARS-CoV-2. J. Med. Chem., 2022, 65(24), 16252-16267. doi: 10.1021/acs.jmedchem.2c00954 PMID: 36503248
  3. Ullrich, S.; Nitsche, C. SARS‐CoV‐2 papain‐like protease: Structure, function and inhibition. ChemBioChem, 2022, 23(19), e202200327. doi: 10.1002/cbic.202200327 PMID: 35993805
  4. Alzyoud, L.; Ghattas, M.A.; Atatreh, N. Allosteric binding sites of the SARS-CoV-2 main protease: Potential targets for broad-spectrum anti-coronavirus agents. Drug Des. Devel. Ther., 2022, 16, 2463-2478. doi: 10.2147/DDDT.S370574 PMID: 35941927
  5. Cherqaoui, D.; Oubahmane, M.; Hdoufane, I.; Bjij, I.; Lahcen, N.A.; Villemin, D.; Daoud, R.; Allali, A.E. Host cell proteases mediating SARS-CoV-2 entry: An overview. Curr. Top. Med. Chem., 2022, 22(21), 1776-1792. doi: 10.2174/1568026622666220726122339 PMID: 35894476
  6. Hu, Q.; Xiong, Y.; Zhu, G.H.; Zhang, Y.N.; Zhang, Y.W.; Huang, P.; Ge, G.B. The SARS-CoV-2 main protease (Mpro): Structure, function, and emerging therapies for COVID-19. MedComm, 2020, 3(3), e151. doi: 10.1002/mco2.151
  7. Ng, T.I.; Correia, I.; Seagal, J.; DeGoey, D.A.; Schrimpf, M.R.; Hardee, D.J.; Noey, E.L.; Kati, W.M. Antiviral drug discovery for the treatment of COVID-19 infections. Viruses, 2022, 14(5), 961. doi: 10.3390/v14050961 PMID: 35632703
  8. Cannalire, R.; Cerchia, C.; Beccari, A.R.; Di Leva, F.S.; Summa, V. Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: State of the art and future opportunities. J. Med. Chem., 2022, 65(4), 2716-2746. doi: 10.1021/acs.jmedchem.0c01140 PMID: 33186044
  9. Adedeji, A.O.; Sarafianos, S.G. Antiviral drugs specific for coronaviruses in preclinical development. Curr. Opin. Virol., 2014, 8, 45-53. doi: 10.1016/j.coviro.2014.06.002 PMID: 24997250
  10. Amin, S.A.; Banerjee, S.; Ghosh, K.; Gayen, S.; Jha, T. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors. Bioorg. Med. Chem., 2021, 29, 115860. doi: 10.1016/j.bmc.2020.115860 PMID: 33191083
  11. Dragovich, P.S.; Webber, S.E.; Babine, R.E.; Fuhrman, S.A.; Patick, A.K.; Matthews, D.A.; Lee, C.A.; Reich, S.H.; Prins, T.J.; Marakovits, J.T.; Littlefield, E.S.; Zhou, R.; Tikhe, J.; Ford, C.E.; Wallace, M.B.; Meador, J.W., III; Ferre, R.A.; Brown, E.L.; Binford, S.L.; Harr, J.E.V.; DeLisle, D.M.; Worland, S.T. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. J. Med. Chem., 1998, 41(15), 2806-2818. doi: 10.1021/jm980068d PMID: 9667970
  12. Vandyck, K.; Abdelnabi, R.; Gupta, K.; Jochmans, D.; Jekle, A.; Deval, J.; Misner, D.; Bardiot, D.; Foo, C.S.; Liu, C.; Ren, S.; Beigelman, L.; Blatt, L.M.; Boland, S.; Vangeel, L.; Dejonghe, S.; Chaltin, P.; Marchand, A.; Serebryany, V.; Stoycheva, A.; Chanda, S.; Symons, J.A.; Raboisson, P.; Neyts, J. ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian hamster model. Biochem. Biophys. Res. Commun., 2021, 555, 134-139. doi: 10.1016/j.bbrc.2021.03.096 PMID: 33813272

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bentham Science Publishers, 2024